Mikael Dolsten, Pfizer

2014 pay package: $7.3 million
2013 pay package: $6.5 million
Change: +12.3%
2014 compensation: $1.2 million in salary; $1.9 million in stock awards; $1.8 million worth of options; $1.3 million in nonequity incentive pay; $938,593 in pension contributions and deferred compensation earnings; and $156,180 in other compensation

Pfizer's ($PFE) Mikael Dolsten saw his paycheck return to growth after three years of gradual dips, bolstered by a jump in stock awards and earnings on deferred compensation. His raise, according to Pfizer, was tied to a pair of FDA approvals, the launch of four Phase III trials, and the signing of 9 asset-related deals and 10 major technology tie-ups.

After Pfizer got rebuffed by AstraZeneca ($AZN) in a protracted buyout gambit, Dolsten and his R&D team had to pivot to Plan B to grow the company's pipeline. Despite its revenue success, Pfizer has long lagged its rivals in some of the industry's hottest fields, including immuno-oncology and rare diseases, and the company's desire for AstraZeneca was in part an effort to fill some pipeline gaps.

Playing catch-up, Pfizer returned to the dealmaking table, paying $850 million up front to partner up on Merck KGaA's avelumab, an antibody to PD-L1 that has shown promise in unblinding the immune system to cancerous growths in the body. Pfizer followed that with a smaller agreement with iTeos Therapeutics in exchange for some preclinical immunotherapies with a different target.

And, buying into gene therapy's second honeymoon, Pfizer signed a $280 million deal with IPO darling Spark Therapeutics ($SPRK) to partner up on a one-time treatment for hemophilia B. Furthering the company's efforts in rare diseases, Pfizer also bought into OPKO's in-development therapy for growth hormone deficiency.

Pfizer's biggest R&D coup of the year came with the lightning-fast approval of Ibrance, a homegrown treatment for breast cancer expected to bring in sales between $3 billion and $5 billion a year at its peak. And the company is bringing up the rear in the race to commercialize a new class of cardiovascular treatments, as its PCSK9-blocking bococizumab is progressing through late-stage development behind antibodies from Amgen ($AMGN) and partners Sanofi ($SNY) and Regeneron ($REGN).

- here's the proxy (PDF)

For more:
Special Report:
The top R&D spenders in biopharma in 2013 - Pfizer: R&D gets smaller, simpler and not very exciting
Playing catch-up, Pfizer looks to leapfrog Big Pharma's immuno-oncology line
Pfizer powers into immuno-oncology with $2.85B R&D pact with Merck KGaA
Post-restructuring, Pfizer R&D focused on its top blockbuster prospects
Pfizer unveils $100M Boston effort to spark R&D innovation

Mikael Dolsten, Pfizer
Read more on

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.